Galectin-1 (GAL1) reprograms the TECs to upregulate PD-L1 and death signal GAL9 and therefore drives T cell exclusion from the TME and is shown to exacerbate immunotherapy resistance in head and neck cancer (Nambiar et al., 2019). This evidence concerns the gene LGALS1 and head and neck cancer.